References
- 1. Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550.10.3389/fimmu.2016.00550514952328018338
- 2. Hoesli R, Birkeland AC, Rosko AJ et al. Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma. Oral Oncol. 2018; 77:83-89.10.1016/j.oraloncology.2017.12.003589710329362129
- 3. Vassilakopoulou M, Avgeris M, Velcheti V, et al. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. Clin Cancer Res. 2016;22(3):704-713.10.1158/1078-0432.CCR-15-154326408403
- 4. Ismail M, Wakiel HE l., Ghany DA, Shakweer MM, Lotfy A, Gaballah AM. 132P - Correlation between tumour infiltration lymphocyte and PDL-1 expression in laryngeal cancer and its prognostic significance: A prospective, non-interventional trial. Ann Oncol. 2019;30:xi49.10.1093/annonc/mdz452.003
- 5. Jia YQ, Yang B, Wen LL, Mu WX, Wang Z, Cheng B. Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis. Aging (Albany NY). 2019;11(2):501-522.10.18632/aging.101756636699030668545
- 6. Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878.10.1038/s41598-017-17204-5571511029203879
- 7. Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550.10.3389/fimmu.2016.00550
- 8. IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.
- 9. Karpathiou G, Casteillo F, Giroult JB, et al. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immunosuppressive pathways and clinicopathologic characteristics. Oncotarget. 2017;8(12):19310-19322.10.18632/oncotarget.14242538668628038471
- 10. Cojocaru Oana, Aschie Mariana, Mocanu Liliana, Baltatescu Gabriela IzabelaLaryngeal primary malignant melanoma: a case report, Rom J Morphol Embryol 2015, 56(4):1513–1516
- 11. Harasymczuk M, Gooding W, Kruk-Zagajewska A, Wojtowicz J, Dworacki G, Tomczak H, et al. Head and neck squamous carcinomas with exophytic and endophytic type of growth have the same prognosis after surgery and adjuvant radiotherapy. Eur Arch oto-rhino-laryngology Off J Eur Fed Oto-Rhino-Laryngological Soc Affil with Ger Soc Oto-Rhino-Laryngology - Head Neck Surg. 2013 Mar;270(3):1105–14.10.1007/s00405-012-2117-1381809422865105
- 12. Rathore AS, Kumar S, Konwar R, Makker A, Negi MP, Goel MM. CD3ţ, CD4ţ and CD8ţ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast., Indian J Med Res 2014;140:361–9.
- 13. Badoual C. Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers. Clin Cancer Res. 2006; 12: 465–72.10.1158/1078-0432.CCR-05-188616428488
- 14. Rittà M, Landolfo V, Mazibrada J, De Andrea M, Dell’Oste V, Caneparo V, Peretti A, Giordano C, Pecorari G, Garzaro M, Landolfo S. Human papillomavirus tumor-infiltrating T-regulatory lymphocytes and P53 codon 72 polymorphisms correlate with clinical staging and prognosis of oropharyngeal cancer. New Microbiol. 2013; 36: 133–44.
- 15. Zandberg DP, Strome SE. The role of the PD-L1/PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncology. 2014; p. 627–32.10.1016/j.oraloncology.2014.04.00324819861
- 16. Takada K, Toyokawa G, Okamoto T, Akamine T, Takamori S, Katsura M, et al. An Immunohistochemical Analysis of PD-L1 Protein Expression in Surgically Resected Small Cell Lung Cancer Using Different Antibodies and Criteria. Anticancer Res. 2016 Jul;36(7):3409–12.
- 17. Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishop JA, Chen L, Drake CG, Topalian SL, et al. Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013; 73: 1733–41.10.1158/0008-5472.CAN-12-2384360240623288508
- 18. Lin YM, Sung WW, Hsieh MJ, Tsai SC, Lai HW, Yang SM, Shen KH, Chen MK, Lee H, Yeh KT, Chen CJ. High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. PLoS One. 2015; 10: e0142656.10.1371/journal.pone.0142656464296726562534
- 19. Cho YA, Yoon HJ, Lee J Il, Hong SP, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011; 47: 1148–53.10.1016/j.oraloncology.2011.08.00721911310
- 20. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011; 28:682–8.10.1007/s12032-010-9515-220373055
- 21. Song M, Chen D, Lu B, Wang C, Zhang J, Huang L, et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One. 2013;8(6):e65821.10.1371/journal.pone.0065821368186723785454
- 22. Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 2013;1:54–63.10.1158/2326-6066.CIR-13-0034388597824416729
- 23. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013;49:2233–42.10.1016/j.ejca.2013.02.01523478000
- 24. Balermpas P, Rodel F, Liberz R, Oppermann J, Wagenblast J, Ghanaati S, et al. Head and neck cancer relapse after chemoradiotherapy correlates with CD163ţ macrophages in primary tumour and CD11bţ myeloid cells in recurrences. Br J Cancer 2014;111:1509–18.10.1038/bjc.2014.446420008925093488
- 25. Gooden MJ, de Bock GH, Leffers N, Daemen T, NijmanHW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011;105:93–103.10.1038/bjc.2011.189313740721629244
- 26. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20: 5064–7410.1158/1078-0432.CCR-13-3271418500124714771